Table 1.

Patient, care, country characteristics, and gout health outcomes and patient-experienced outcomes overall and per geographic region.

Western Europe, n = 331Middle Europe, n = 210Southern Europe, n = 388Northern Europe, n = 100Total, n = 1029
Patient characteristics
    Females70 (21)43 (21)88 (23)27 (27)228 (22)
    Age > 55 yrs221 (64)118 (56)166 (43)59 (59)554 (54)
    Higher education146 (44)46 (22)181 (47)25 (25)398 (39)
    Employed124 (38)105 (50)242 (62)41 (41)512 (50)
    Comorbidities, mean (0–5)1.5 (1.3)1.8 (1.4)2.0 (1.6)1.5 (1.2)1.8 (1.5)
    Knowledgeable about disease104 (31)58 (28)228 (59)20 (20)410 (40)
    Knowledgeable about lifestyle235 (71)187 (89)332 (86)75 (75)829 (81)
Care characteristics
    Treated with ULT179 (54)116 (55)262 (68)47 (47)604 (59)
    Regular follow-ups (≥ 2)141 (43)93 (44)172 (44)17 (17)423 (41)
    Diagnosed by GP258 (78)150 (71)262 (68)76 (76)746 (73)
Country characteristicsa, mean (SD)
    GDP (Int$, in thousands)53.4 (10.2)56.6 (4.9)41.3 (2.1)58.2 (5.5)49.9 (9.5)
    HCE (Int$, in thousands)5.0 (0.1)6.1 (0.5)3.4 (0.1)5.6 (0.3)4.7 (1.1)
Gout health outcomes
    ≥ 3 gout flares in past year106 (32)61 (29)116 (30)41 (41)324 (32)
    ≥ 1 gout flare in past year235 (71)128 (61)296 (76)65 (65)724 (70)
Patient-experienced outcomes
    Impact of gout on mental and physical health131 (40)60 (29)218 (56)34 (34)443 (43)
    Missed ≥ 1 day of workb58 (47)51 (49)140 (58)15 (37)264 (52)
    Satisfaction with current medication273 (83)165 (79)306 (79)74 (74)818 (80)
    Unaddressed treatment goals (0–9), mean (SD)1.1 (1.3)1.1 (1.3)1.2 (1.1)1.2 (1.4)1.1 (1.2)
  • Values are expressed as n (%) unless otherwise indicated.

  • aInternational dollars (Int$) extracted from the Organisation for Economic Co-operation and Development (2018 or latest available; www.oecd.org).

  • bOnly employed patients (512/1029 [50%]). GDP: gross domestic product; GP: general practitioner; HCE: healthcare expenditures; ULT: urate-lowering therapy.